SJEPD031_R.RNA-Seq
EPN · Posterior Fossa EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Posterior Fossa EPN
- cancer_type
- EPN
- subtype
- Posterior Fossa EPN
- age_years
- 2.54
- e1_e2
- E2
- umap1_2d
- -6.748841455
- umap2_2d
- -0.342197068
- umap1_3d
- 0.487436489
- umap2_3d
- 3.208426246
- umap3_3d
- 1.075476667
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- BILE_ACID_METABOLISM+0.290
- MYOGENESIS+0.240
- KRAS_SIGNALING_DN+0.230
- GLYCOLYSIS+0.130
- ESTROGEN_RESPONSE_EARLY+0.120
- SPERMATOGENESIS+0.120
- UV_RESPONSE_UP+0.120
- WNT_BETA_CATENIN_SIGNALING+0.120
- COAGULATION+0.090
- NOTCH_SIGNALING+0.090
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.340
- PROTEIN_SECRETION-0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.340
- INTERFERON_GAMMA_RESPONSE-0.330
- INTERFERON_ALPHA_RESPONSE-0.320
- ALLOGRAFT_REJECTION-0.300
- MYC_TARGETS_V1-0.300
- PI3K_AKT_MTOR_SIGNALING-0.290
- CHOLESTEROL_HOMEOSTASIS-0.260
- MITOTIC_SPINDLE-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MBCProject_0988_T3_RNA | — | A | 0.777 |
| 2 | ERR2208949 | — | — | 0.767 |
| 3 | BS_YE1MAQYJ | Spinal Cord Ependymoma | — | 0.760 |
| 4 | TCGA-D8-A3Z5-01A-41R-A24H-07 | — | A | 0.758 |
| 5 | TCGA-E7-A4XJ-01A-11R-A26T-07 | — | — | 0.756 |
| 6 | DRR168553 | — | — | 0.754 |
| 7 | R76 | — | — | 0.753 |
| 8 | MDT-AP-0530 | Med | Medulloblastoma | 0.752 |
| 9 | BS_MKP2Y41Z | Posterior Fossa Ependymoma | — | 0.752 |
| 10 | AUR-AEPZ-TTP1-A-1-1-R-A742-41 | — | B | 0.751 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| BILE_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| MYOGENESIS | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.230 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.120 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.120 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.120 | Inavolisib | — uncovered |
| COAGULATION | 0.090 | Binimetinib | — uncovered |
| NOTCH_SIGNALING | 0.090 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.080 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.080 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.060 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.050 | Inavolisib | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.030 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.030 | Inavolisib | — uncovered |
| HYPOXIA | 0.020 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.010 | Idelalisib | — uncovered |